Scarica l'app Stockscreener
24.97
4.40%
-1.15
Dopo l'orario di chiusura:
24.97
Precedente Chiudi:
$26.12
Aprire:
$25.69
Volume 24 ore:
729.85K
Relative Volume:
0.56
Capitalizzazione di mercato:
$2.84B
Reddito:
$4.02M
Utile/perdita netta:
$-224.59M
Rapporto P/E:
-10.49
EPS:
-2.3795
Flusso di cassa netto:
$-205.52M
1 W Prestazione:
-8.06%
1M Prestazione:
-2.80%
6M Prestazione:
+14.23%
1 anno Prestazione:
+177.44%
Intervallo 1D:
$24.91
$26.08
Intervallo di 1 settimana:
$24.91
$27.25
Portata 52W:
$8.925
$30.06
Immunome Inc Stock (IMNM) Company Profile
Nome
Immunome Inc
Settore
Industria
Telefono
610-321-3700
Indirizzo
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
24.97 | 2.97B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-28 | Iniziato | Barclays | Overweight |
| 2026-02-12 | Iniziato | H.C. Wainwright | Buy |
| 2025-12-01 | Iniziato | Truist | Buy |
| 2025-09-22 | Iniziato | Goldman | Buy |
| 2025-09-05 | Iniziato | Craig Hallum | Buy |
| 2025-04-02 | Iniziato | Lake Street | Buy |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-04-30 | Iniziato | JP Morgan | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-01-29 | Iniziato | Leerink Partners | Outperform |
| 2023-12-19 | Iniziato | Wedbush | Outperform |
| 2021-10-29 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Immunome Inc Borsa (IMNM) Ultime notizie
IMNM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome, Inc. Revenue Breakdown – NASDAQ:IMNM - TradingView
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Immunome (NASDAQ:IMNM) Is In A Good Position To Deliver On Growth Plans - Moomoo
(IMNM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunome (IMNM) Reports A Wider Loss, Is The Premium Valuation Justified? - Sahm
Immunome (IMNM) Update: Closes 0.98% Lower at $28.24 at the Close; Chart Watch: Traders Can Monitor the $26.83-$29.65 Range in the Current UpdateCommon Gap - siam.in
Immunome (IMNM) Results Review: EPS Clears the Reported Estimate for the Current Session; Closing Move - dars.gov.et
Should Immunome’s (IMNM) Rising Losses and ESOP Shelf Offering Require Action From Investors? - Sahm
Enterprise value to revenue forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Bank of America Corp DE Boosts Stake in Immunome, Inc. $IMNM - MarketBeat
IMNM|Immunome Inc|Price:28.520|Chg%:+0.440 - TradingKey
Enterprise value to EBIT forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Immunome (NASDAQ:IMNM) Sets New 12-Month HighShould You Buy? - MarketBeat
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration - Sahm
Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
IMNM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline at Pre-Revenue Oncology BiotechBuyback Announcement Report - vinanet.vn
Is Immunome’s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story? - Sahm
Immunome director Isaac Barchas sells $940,453 in common stock - Investing.com
Dimensional Fund Advisors LP Decreases Stock Position in Immunome, Inc. $IMNM - MarketBeat
Immunome (IMNM) Is Up 8.7% After Wider Loss And ESOP Shelf Filing What’s Changed - simplywall.st
Immunome (NASDAQ:IMNM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Immunome (IMNM) Q1 2026 Earnings: Narrower-than-Expected Loss Drives 2.95% Stock GainRevenue Miss Report - vinanet.vn
IMNM Q1 2026 Earnings: Narrower Net Loss Beats on Cost ControlPerformance Review - vinanet.vn
T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5% - Stock Titan
Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A - Stock Titan
HC Wainwright Issues Negative Forecast for Immunome Earnings - MarketBeat
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon (IMNM) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Immunome (IMNM) - The Globe and Mail
Renaissance Technologies LLC Makes New Investment in Immunome, Inc. $IMNM - MarketBeat
Immunome gets FDA nod for varegacestat NDA, sets PDUFA date for April 2027 - Pluang
Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 Shares - MarketBeat
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 11,048 Shares - MarketBeat
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells $1,633,892.93 in Stock - MarketBeat
Immunome director Isaac Barchas sells over $2.1m in shares By Investing.com - Investing.com South Africa
Immunome director Isaac Barchas sells over $2.1m in shares - Investing.com
Immunome, Inc. Stock 12‑Month Price Target Raised to $36.31, Implies 38% Upside - TradingView
IMNM Maintains Buy Rating by Truist Securities -- Price Target R - GuruFocus
Immunome (NASDAQ:IMNM) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Immunome, Inc. Stock 12‑Month Price Target Raised to $36.15, Implies 38% Upside - TradingView
IMNM Maintains Outperform by Wedbush -- Price Target Raised to $35 - GuruFocus
Immunome stock hits 52-week high at 27.68 USD By Investing.com - Investing.com South Africa
Immunome stock hits 52-week high at 27.68 USD - Investing.com
Immunome Inc. SEC Filing (Aug 12, 2026) - Stock Titan
Evercore Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Immunome (NASDAQ:IMNM) Shares Gap Down on Disappointing Earnings - MarketBeat
A Quick Look at Today's Ratings for Immunome(IMNM.US), With a Forecast Between $33 to $40 - Moomoo
Immunome Inc Azioni (IMNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):